Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Income from Continuing Operations (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Income from Continuing Operations data on record, last reported at 42526.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 498.44% year-over-year to 42526.0; the TTM value through Dec 2025 reached 101146.0, down 139.13%, while the annual FY2025 figure was 101146.0, 139.13% down from the prior year.
  • Income from Continuing Operations reached 42526.0 in Q4 2025 per ACBM's latest filing, up from 117809.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2224221.0 in Q4 2021 and bottomed at 4011322.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 1322162.65, with a median of 88651.5 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: surged 3700.75% in 2021, then plummeted 6503.69% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 2224221.0 in 2021, then plummeted by 276.9% to 3934681.0 in 2022, then surged by 99.54% to 18240.0 in 2023, then skyrocketed by 41.49% to 10673.0 in 2024, then skyrocketed by 498.44% to 42526.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 42526.0 in Q4 2025, 117809.0 in Q3 2025, and 15562.0 in Q2 2025.